Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-09-06Clinical Trial Update: Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment [Phase 1]
A Phase 1 trial evaluating the combination of ixazomib and pevonedistat in patients with recurrent or refractory multiple myeloma has comple…
-
CLINICAL_TRIALS trial_result · 2023-09-06Clinical Trial Update: CURATE.AI Optimized Modulation for Multiple Myeloma [Phase 2, Phase 3]
Clinical trial update for CURATE.AI optimized modulation in multiple myeloma across Phase 2 and Phase 3.
-
CLINICAL_TRIALS trial_result · 2023-08-28Clinical Trial Update: Efficacy of Daratumumab in Patients With Relapsed/Refractory Myeloma With Renal Impairment [Phase 2]
Phase 2 trial evaluating daratumumab in relapsed/refractory multiple myeloma with renal impairment has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-08-28Clinical Trial Update: Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody. [Phase 1, Phase 2]
Clinical trial update for a humanized CAR-T targeting BCMA (ARI0002h) in relapsed/refractory multiple myeloma, undergoing Phase 1/Phase 2 ev…
-
CLINICAL_TRIALS trial_result · 2023-08-22Clinical Trial Update: A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy [Phase 3]
Phase 3 trial evaluating venetoclax in combination with bortezomib and dexamethasone for relapsed/refractory multiple myeloma has completed …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-08-22Clinical Trial Update: Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM) [Phase 2]
Phase 2 trial evaluating Pembrolizumab plus Lenalidomide after autologous stem cell transplant in high-risk multiple myeloma was terminated;…
-
CLINICAL_TRIALS trial_result · 2023-08-22Clinical Trial Update: Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]
Phase 1/2 trial evaluating AO-176 as monotherapy and in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma ha…
-
CLINICAL_TRIALS trial_result · 2023-08-21Clinical Trial Update: Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma [Phase 2]
Phase 2 trial of nivolumab, ixazomib, cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma was terminated with result…
-
FDA approval · 2023-08-18FDA Approved: IVRA — Original Application (Apotex Corp)
FDA approved Apotex Corp's original application for IVRA, an intravenous melphalan hydrochloride formulation.
-
EMA approval · 2023-08-17EMA Authorised: Nexpovio (selinexor) — Stemline Therapeutics B.V.
EU authorization of Nexpovio (selinexor) for multiple myeloma, with Stemline Therapeutics B.V. as MAH, decision dated 14 August 2023.
-
FDA approval · 2023-08-14FDA Approved: ELREXFIO — Original Application (U.S. Pharmaceuticals)
FDA approved ELREXFIO (elranatamab-BCMM) via an Original Application for use in adults with multiple myeloma.
-
FDA approval · 2023-08-09FDA Approved: TALVEY — Original Application (Janssen Biotech, Inc.)
FDA approves TALVEY (talquetamab) from Janssen Biotech as an original Biologics License Application for adults with multiple myeloma who hav…
-
FDA approval · 2023-08-09FDA Approved: TECVAYLI — Supplemental Application (Janssen Biotech, Inc.)
The FDA approved Janssen Biotech's supplemental application for TECVAYLI (teclistamab-cqyv), resulting in an updated/expanded labeling for t…
-
CLINICAL_TRIALS trial_result · 2023-08-04Clinical Trial Update: Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2) [Phase 2]
A Phase 2 MATCH-subprotocol trial is evaluating trametinib for cancers with GNAQ or GNA11 mutations; the study is active/not recruiting and …
-
CLINICAL_TRIALS trial_result · 2023-08-04Clinical Trial Update: A Study Of Daratumumab, Low-Dose Oral Dexamethasone and Cyclophosphamide With Or Without Pomalidomide [Phase 2]
Phase 2 clinical trial evaluating daratumumab with low-dose dexamethasone and cyclophosphamide, with or without pomalidomide, in relapsed or…
-
CLINICAL_TRIALS trial_result · 2023-08-04Clinical Trial Update: Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma [Phase 2]
A Phase 2 trial evaluates lenalidomide plus melphalan in patients with previously untreated multiple myeloma.
-
CLINICAL_TRIALS trial_result · 2023-08-04Clinical Trial Update: A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma [Phase 2]
Phase 2 clinical trial update for AT9283 in relapsed or refractory multiple myeloma has completed.
-
CLINICAL_TRIALS trial_result · 2023-08-03Clinical Trial Update: Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06) [Phase 2]
Phase 2 clinical trial evaluating a triplet regimen (MLN9708, Lenalidomide, Dexamethasone) for newly diagnosed multiple myeloma; study compl…
-
CLINICAL_TRIALS trial_result · 2023-08-02Clinical Trial Update: Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1) [Phase 2]
Phase 2 MATCH subprotocol study evaluating trametinib for cancers with NF1 genetic changes has posted results; the trial is currently not re…
-
FDA approval · 2023-07-26FDA Approved: PLERIXAFOR — Original Application (Zydus Lifesciences Limited)
FDA approved the original generic application for Plerixafor, enabling Zydus Lifesciences Limited to market the drug in the United States.
-
FDA approval · 2023-07-24FDA Approved: PLERIXAFOR — Original Application (Meitheal Pharmaceuticals Inc.)
FDA approved a generic version of plerixafor (Meitheal Pharmaceuticals) via an Original Application, enabling broader access for hematopoiet…
-
CLINICAL_TRIALS trial_result · 2023-07-24Clinical Trial Update: A Study to Desensitize Allergic Reactions to Treatments for Blood Disorders [Phase 2]
Phase 2 clinical trial update on desensitization for allergic reactions to treatments used for blood disorders, completed.
-
FDA approval · 2023-07-24FDA Approved: PLERIXAFOR — Original Application (Dr. Reddy's Laboratories Inc)
FDA approved the original application for a generic Plerixafor (PLERIXAFOR) manufactured by Dr. Reddy's Laboratories Inc.
-
FDA approval · 2023-07-24FDA Approved: PLERIXAFOR — Original Application (Novadoz Pharmaceuticals LLC)
FDA approved a generic version of Plerixafor (Novadoz Pharmaceuticals LLC) under an Original Application (ANDA) for mobilizing hematopoietic…
-
FDA approval · 2023-07-24FDA Approved: PLERIXAFOR — Original Application (Eugia US LLC)
FDA approved the original abbreviated new drug application for Plerixafor by Eugia US LLC, enabling its generic entry for stem cell mobiliza…